首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Validated stability-indicating HPLC method for the determination of pridinol mesylate. Kinetics study of its degradation in acid medium.
【24h】

Validated stability-indicating HPLC method for the determination of pridinol mesylate. Kinetics study of its degradation in acid medium.

机译:经验证的稳定性指示HPLC方法测定甲磺酸普瑞地诺。在酸性介质中降解的动力学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The stability of pridinol mesylate (PRI) was investigated under different stress conditions, including hydrolytic, oxidative, photolytic and thermal, as recommended by the ICH guidelines. Relevant degradation was found to take place under acidic (0.1N HCl) and photolytic (visible and long-wavelength UV-light) conditions, both yielding the product resulting from water elimination (ELI), while submission to an oxidizing environment gave the N-oxidation derivative (NOX). The standards of these degradation products were synthesized and characterized by IR, (1)H and (13)C NMR spectroscopy. A simple, sensitive and specific HPLC method was developed for the quantification of PRI, ELI and NOX in bulk drug, and the conditions were optimized by means of a statistical design strategy. The separation employs a C(18) column and a 51:9:40 (v/v/v) mixture of MeOH, 2-propanol and potassium phosphate solution (50mM, pH 6.0), as mobile phase, delivered at 1.0 ml min(-1); the analytes were detected and quantified at 220 nm. The method was validated, demonstrating to be accurate and precise (repeatability and intermediate precision levels) within the corresponding linear ranges of PRI (0.1-1.5 mg ml(-1); r=0.9983, n=18) and both impurities (0.1-1.3% relative to PRI, r=0.9996 and 0.9995 for ELI and NOX, respectively, n=18). Robustness against small modifications of pH and percentage of the aqueous mobile phase was ascertained and the limits of quantification of the analytes were also determined (0.4 and 0.5 microg ml(-1); 0.04% and 0.05% relative to PRI for ELI and NOX, respectively). Peak purity indices (>0.9997), obtained with the aid of diode-array detection, and satisfactory resolution (R(s)>2.0) between PRI and its impurities established the specificity of the determination, all these results proving the stability-indicating capability of the method. The kinetics of the degradation of PRI in acid medium was also studied, determining that this is a first-order process with regards to drug concentration, with an activation energy of 25.5 Kcal mol(-1) and a t(1/2)=10,830 h, in 0.1N HCl at 38 degrees C.
机译:按照ICH指南的建议,研究了甲磺酸普瑞汀醇(PRI)在不同应力条件下的稳定性,包括水解,氧化,光解和热应力。发现在酸性(0.1N HCl)和光解(可见光和长波长紫外光)条件下会发生相关降解,两者都产生于除水(ELI)产生的产物,而在氧化环境中,N-氧化衍生物(NOX)。合成了这些降解产物的标准品,并通过IR,(1)H和(13)C NMR光谱进行了表征。开发了一种简单,灵敏且特异的HPLC方法,用于定量散装药物中的PRI,ELI和NOX,并通过统计学设计策略优化了条件。分离使用C(18)柱和MeOH,2-丙醇和磷酸钾溶液(50mM,pH 6.0)的51:9:40(v / v / v)混合物作为流动相,以1.0 ml min的流速输送(-1);检测到的分析物在220 nm处定量。该方法经过验证,证明在PRI(0.1-1.5 mg ml(-1); r = 0.9983,n = 18)和两种杂质(0.1-1.5%)的相应线性范围内都是准确,准确的(重复性和中等精度水平)。相对于PRI为1.3%,ELI和NOX分别为r = 0.9996和0.9995,n = 18)。确定了对pH值和水性流动相百分比的小幅修改的稳健性,并且还确定了分析物的定量限(0.4和0.5 microg ml(-1);相对于PRI,ELI和NOX为0.04%和0.05%,分别)。借助于二极管阵列检测获得的峰纯度指数(> 0.9997)以及PRI及其杂质之间的令人满意的分辨率(R(s)> 2.0)确定了测定的特异性,所有这些结果证明了稳定性指示能力该方法。还研究了PRI在酸性介质中降解的动力学,确定这是药物浓度的一级过程,活化能为25.5 Kcal mol(-1),at(1/2)= 10,830 h,在38°C下于0.1N HCl中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号